Sold as Niclocide. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Niclosamide (sold as Niclocide), with 0 new uses approved and 0 published complete response letters.
| Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate CancerCastration-Resistant Prostate Cancer (CRPC) · Hyundai Bioscience Co., Ltd. | Phase 1 | Not yet recruiting | Jul 6, 2026 |
| Niclosamide in Pediatric Patients With Relapsed and Refractory AMLAcute Myeloid Leukemia (AML) · Stanford University | Phase 1 | Recruiting | Jan 12, 2022 |
| Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate CancerMetastatic Prostate Carcinoma, Recurrent Prostate Carcinoma · Mamta Parikh | Phase 2 | Active, not recruiting | Jun 21, 2016 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| — | NiclocideNDA 18669 | Bayer Pharms | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
